Standing together in support of improved access to obesity care
Learn more about how we’re supporting The Obesity Society and their recent consensus statement on obesity to help raise awareness and improve access to care for people living with this chronic medical condition.
Thorsten von Goessel of Engineering & Facilities, describes Boehringer Ingelheim as family business with long-term perspective and wonderful leadership team.
It can be hard for people living without schizophrenia to realize its burdens. Understanding these challenges can provide insights to help patients in need.
Lamine Mbow, our Global Head of Cancer Immunology and Immune Modulation, shares our approach to immuno-oncology, highlighting our investigational T-cell engagers platform and how we are driving innovation to potentially deliver meaningful advances to peop
Initial results from EMPRISE real-world evidence study show Jardiance® was associated with reduced risk for hospitalization for heart failure compared with DPP-4 inhibitors in people with type 2 diabetes with and without cardiovascular disease
Initial results from EMPRISE real-world evidence study show Jardiance® was associated with reduced risk for hospitalization for heart failure compared with DPP-4 inhibitors in people with type 2 diabetes with and without cardiovascular disease
We drive innovation across our complex business landscape at Boehringer Ingelheim. Technology is an integral part of our core business processes and we focus on advanced technologies.